I’ve been a bit surprised about discontinuing RC110, thought bundling that for AML might have been a way to get to early license/partnership to bring in some cash, raise sp to a base where further cash raising could be done from a decent sp. and minimise dilution, to fund the bigger opportunities with RC220 in breast cancer+ cardio protect and FTO.
be interesting to see what comes of the retuned plan.
Ann: Appendix 4E & Annual Report, page-21
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.60 |
Change
-0.005(0.31%) |
Mkt cap ! $272.6M | |||
| Open | High | Low | Value | Volume |
| $1.62 | $1.62 | $1.60 | $22.77K | 14.14K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2932 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 700 | 1 |
View Market Depth
| Last trade - 10.24am 09/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |